SBH
HRMY icon

Segall Bryant & Hamill’s Harmony Biosciences HRMY Stock Holding History

Segall Bryant & Hamill’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$842K Buy
30,059
+11,841
+65% +$388K 0.01% 528
2025
Q4 		$682K Buy
+18,218
New +$599K 0.01% 532

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Segall Bryant & Hamill's HRMY Position: Q1 2026 in Review

Segall Bryant & Hamill increased its Harmony Biosciences (HRMY) stake by 65% in Q1 2026, buying an estimated $388K and bringing the position to 30,059 shares worth $842K. The position accounts for 0.01% of the portfolio, ranked #528.

Segall Bryant & Hamill first reported a position in HRMY in Q4 2025 and has held it in 2 quarters since. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Segall Bryant & Hamill held 30,059 shares of Harmony Biosciences worth $842K as of Q1 2026.
  • Segall Bryant & Hamill bought 11,841 Harmony Biosciences shares in Q1 2026, an estimated $388K.
  • Harmony Biosciences made up 0.01% of Segall Bryant & Hamill's portfolio in Q1 2026, its #528 holding.
  • Segall Bryant & Hamill first reported a position in Harmony Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Segall Bryant & Hamill's 13F filing for Q1 2026, filed 15 May 2026.